Bright Minds Biosciences (DRUG) Capital Leases (2022 - 2025)

Bright Minds Biosciences (DRUG) posted Capital Leases of $12006.9 for Q4 2025, down 59.94% on a QoQ basis from $29973.0 in Q3 2025.

Bright Minds Biosciences (DRUG) Capital Leases (2022 - 2025) Analysis & Trends

Bright Minds Biosciences' Capital Leases history runs 4 years deep, the most recent figure standing at $12006.9 for Q4 2025.

Quarterly Capital Leases changed N/A year-over-year to $12006.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12006.9 (changed N/A YoY) and the FY2025 annual result came in at $29973.0, up 3.31% from the prior year.
Capital Leases was $12006.9 for Q4 2025 at Bright Minds Biosciences, down from $29973.0 in the prior quarter.
Across five years, Capital Leases topped out at $61918.2 in Q1 2025 and bottomed at $10434.2 in Q2 2023.
A 4-year average of $34419.9 and a median of $29973.0 in 2025 frame the typical range for Capital Leases.
Peak annual rise in Capital Leases reached 3.31% in 2025, while the deepest fall reached 3.31% in 2025.
Bright Minds Biosciences' Capital Leases stood at $40197.5 in 2022, then tumbled by 74.04% to $10434.2 in 2023, then surged by 178.04% to $29011.3 in 2024, then tumbled by 58.61% to $12006.9 in 2025.
Business Quant data shows DRUG's Capital Leases at $12006.9 in Q4 2025, $29973.0 in Q3 2025, and $45353.9 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Bright Minds Biosciences	498.53 Mn	498.53 Mn	-

Download Data